To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure email@example.com
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Siong-Seng Liau, Hepatopancreatobiliary Surgery Unit, Department of Surgery, Addenbrooke’s Hospital, and Medical Research Council Cancer Cell Unit, Hutchison-MRC Research Center, University of Cambridge, Cambridge, UK,
David A. Tuveson, Department of Oncology, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
Pancreatic cancer is usually fatal. Various factors have been ascribed to this grim reality, including the lack of early disease detection methods and the poor response of pancreatic patients to therapies (1,2). Surgery is the only curative therapy (Figure 48.1), but only a small minority of patients qualify for surgery (10–20%) and most of these patients still succumb to local or metastatic recurrence. In advanced disease, chemotherapy remains the only option, however few agents are approved and they show only a modest survival benefit. To make progress against this cancer, a better understanding at the molecular and tissue level is urgently required, which should serve as a “roadmap” to identify better therapeutic agents.
Histopathology of pancreatic adenocarcinoma
Pancreatic ductal adenocarcinoma (PDA) is the most common exocrine pancreatic tumor, accounting for 85% of all malignant pancreatic tumors. Histologically, PDA is a malignant epithelial neoplasm which demonstrates gland formation (3). A characteristic feature of PDA is the intense peritumoural desmoplastic reaction (Figure 48.1). PDA evolves through a multi-step process with cells gaining cumulative genetic and phenotypic alterations resulting in pathological progression from normal pancreas to pre-invasive pre-neoplasms and invasive cancer (4; Figure 48.2). These pre-neoplasms include pancreatic intra-epithelial neoplasms (PanINs), intra-ductal papillary mucinous neoplasms (IPMNs), and mucinous cystic neoplasms (MCNs). Compelling evidence supports the notion that PDA develops from pancreatic pre-neoplasms, similar to the proposed adenoma–carcinoma sequence in colorectal adenocarcinoma (5).
Email your librarian or administrator to recommend adding this to your organisation's collection.